Research ArticleClinical Practice Guidelines
Open Access

Saudi experts’ recommendation for RSV prophylaxis in the era of COVID-19

Consensus from the Saudi Pediatric Pulmonology Association

Adel S. Alharbi, Mohamed Alzahrani, Abdulrahman N. Alodayani, Mohamed Y. Alhindi, Saleh Alharbi and Abdulrahman Alnemri
Saudi Medical Journal April 2021, 42 (4) 355-362; DOI: https://doi.org/10.15537/smj.2021.42.4.20200769

References

  1. 1.↵
    1. Halasa N,
    2. Williams J,
    3. Faouri S,
    4. Shehabi A,
    5. Vermund SH,
    6. Wang L, et al.
    Natural history and epidemiology of respiratory syncytial virus infection in the Middle East: hospital surveillance for children under age two in Jordan. Vaccine 2015; 33: 6479–687.
    OpenUrl
  2. 2.↵
    1. Yassine HM,
    2. Sohail MU,
    3. Younes N,
    4. Nasrallah GK.
    Systematic review of the respiratory syncytial virus (RSV) prevalence, genotype distribution, and seasonality in children from the middle east and North Africa (MENA) region. Microorganisms 2020; 8: 713.
    OpenUrl
  3. 3.↵
    1. McNaughten B,
    2. Hart C,
    3. Shields M.
    Management of bronchiolitis in infants: key clinical questions. Paediatr. Child Health (United Kingdom) 2017; 27: 324–327.
    OpenUrl
  4. 4.↵
    World Health Organization. Who Strategy To Pilot Global Respiratory Syncytial Virus Surveillance Based On The Global Influenza Surveillance And Response System (GISRS). (Updated 2017; Cited). Available from URL: https://apps.who.int/iris/handle/10665/259853
  5. 5.↵
    1. Shi T,
    2. McAllister DA,
    3. O’Brien KL,
    4. Simoes EAF,
    5. Madhi SA,
    6. Gessner BD, et al.
    Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390: 946–958.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Albogami SS,
    2. Alotaibi MR,
    3. Alsahli SA,
    4. Masuadi E,
    5. Alshaalan M.
    Seasonal variations of respiratory viruses detected from children with respiratory tract infections in Riyadh, Saudi Arabia. J Infect Public Health 2018; 11: 183–186.
    OpenUrl
  7. 7.↵
    1. Henderson FW,
    2. Collier AM,
    3. Clyde WA,
    4. Denny FW.
    Respiratory-£ren. N Engl J Med 1979; 300: 530–534.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Wright M,
    2. Mullett CJ,
    3. Piedimonte G.
    Pharmacological management of acute bronchiolitis. Ther Clin Risk Manag 2008; 4: 895–903.
    OpenUrlPubMed
  9. 9.↵
    1. Florin TA,
    2. Plint AC,
    3. Zorc JJ.
    Viral bronchiolitis. Lancet 2017; 389: 211–224.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Aherne W,
    2. Bird T,
    3. Court SD,
    4. Gardner PS,
    5. McQuillin J.
    Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970; 23: 7–18.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Alharbi A,
    2. Alqwaiee M,
    3. Al-Hindi M,
    4. Mosalli R,
    5. Al-Shamrani A,
    6. Alharbi S, et al.
    Bronchiolitis in children: The Saudi-initiative of bronchiolitis diagnosis, management, and prevention (SIBRO). Ann Thorac Med 2018; 13: 127–143.
    OpenUrl
  12. 12.↵
    1. Del Vecchio A,
    2. Franco C,
    3. Del Vecchio K,
    4. Umbaldo A,
    5. Capasso L,
    6. Raimondi F.
    RSV prophylaxis in premature infants. Minerva Pediatr 2018; 70: 579–588.
    OpenUrl
  13. 13.↵
    1. Acero-Bedoya S,
    2. Wozniak PS,
    3. Sánchez PJ,
    4. Ramilo O,
    5. Mejias A.
    Recent Trends in RSV immunoprophylaxis: clinical implications for the infant. Am J Perinatol 2019; 36: S63–S67.
    OpenUrlCrossRef
  14. 14.↵
    1. Luna MS,
    2. Manzoni P,
    3. Paes B,
    4. Baraldi E,
    5. Cossey V,
    6. Kugelman A, et al.
    Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev 2020; 33: 35–44.
    OpenUrl
  15. 15.↵
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134: e620–e638.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Pickering LK,
    2. Baker CJ,
    3. Kimberlin DW,
    4. Long SS
    American Academy of Pediatrics. Red book. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2009.
  17. 17.↵
    1. Fagbo SF,
    2. Garbati MA,
    3. Hasan R,
    4. AlShahrani D,
    5. Al-Shehri M,
    6. AlFawaz T, et al.
    Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013. J Med Virol 2017; 89: 195–201.
    OpenUrl
  18. 18.↵
    1. Jamjoom GA,
    2. Al-Semrani AM,
    3. Board A,
    4. Al-Frayh AR,
    5. Artz F,
    6. Al-Mobaireek KF.
    Respiratory syncytial virus infection in young children hospitalized with respiratory illness in Riyadh. J Trop Pediatr 1993; 39: 346–3469.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Al-Hajjar S,
    2. Akhter J,
    3. Al Jumaah S,
    4. Qadri SMH.
    Respiratory viruses in children attending a major referral centre in Saudi Arabia. Ann Trop Paediatr 1998; 18: 87–92.
    OpenUrlPubMed
  20. 20.↵
    1. Meqdam MM,
    2. Subaih SH.
    Rapid detection and clinical features of infants and young children with acute lower respiratory tract infection due to respiratory syncytial virus. FEMS Immunol Med Microbiol 2006; 47: 129–133.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Dhama K,
    2. Khan S,
    3. Tiwari R,
    4. Sircar S,
    5. Bhat S,
    6. Malik YS, et al.
    Coronavirus disease 2019-COVID-19. Clin Microbiol Rev 2020; 33: 1–48.
    OpenUrlCrossRef
  22. 22.↵
    John Hopkins University & Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE). (Updated 2021; Cited). Available from URL: https://systems.jhu.edu
  23. 23.↵
    1. Xiang B,
    2. Li P,
    3. Yang X,
    4. Zhong S,
    5. Manyande A,
    6. Feng M.
    The impact of novel coronavirus SARS-CoV-2 among healthcare workers in hospitals: An aerial overview. Am J Infect Control 2020; 48: 915–917.
    OpenUrl
  24. 24.↵
    1. Lambert PH,
    2. Ambrosino DM,
    3. Andersen SR,
    4. Baric RS,
    5. Black SB,
    6. Chen RT, et al.
    Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine 2020; 38: 4783–8791.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Yezli S,
    2. Khan A.
    COVID-19 social distancing in the Kingdom of Saudi Arabia: Bold measures in the face of political, economic, social and religious challenges. Travel Med Infect Dis 2020; 37: 101692.
    OpenUrl
  26. 26.↵
    1. Alrashed S,
    2. Min-Allah N,
    3. Saxena A,
    4. Ali I,
    5. Mehmood R.
    Impact of lockdowns on the spread of COVID-19 in Saudi Arabia. Informatics Med Unlocked 2020; 20: 100420.
    OpenUrl
  27. 27.↵
    1. Alsofayan YM,
    2. Althunayyan SM,
    3. Khan AA,
    4. Hakawi AM,
    5. Assiri AM.
    Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study. J Infect Public Health 2020; 13: 920–925.
    OpenUrl
  28. 28.↵
    1. Alyami MH,
    2. Naser AY,
    3. Orabi MAA,
    4. Alwafi H,
    5. Alyami HS.
    Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: An Ecological Study. Front Public Heal 2020; 8: 506.
    OpenUrl
  29. 29.↵
    1. Nezar Kobeisy SA,
    2. Harbi S Al,
    3. Mehdawi RS,
    4. Bashammakh DS.
    Pediatric COVID-19 Patients in Jeddah, Saudi Arabia: Clinical, Laboratory and Radiological Aspects. J Biomed Sci 2020; 9: 1–4.
    OpenUrl
  30. 30.↵
    1. Heald-Sargent T,
    2. Muller WJ,
    3. Zheng X,
    4. Rippe J,
    5. Patel AB,
    6. Kociolek LK.
    Age-related differences in nasopharyngeal severe acute respiratory syndrome coronavirus 2 (sars-cov-2) levels in patients with mild to moderate coronavirus disease 2019 (COVID-19). JAMA Pediatr 2020; 174: 902.
    OpenUrl
  31. 31.↵
    Ministry of Health. Neonatology Services Improvement Program. Guidelines for neonates born to mothers with suspected or confirmed COVID-19 infection. (Updated 2021. Cited). Available from URL: https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/Saudi-Guideline-for-Neonate.pdf
  32. 32.↵
    1. Alrabiaah A,
    2. Alshaer A,
    3. Estrella SM,
    4. Inclan KA,
    5. Aljammaz H,
    6. Almoosa K, et al.
    Effects of the Coronavirus disease 2019 pandemic on routine pediatric immunization coverage rates at the main University Hospital in Saudi Arabia. Saudi Med J 2020; 41: 1197–1203.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    AstraZeneca. US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897. [Updated 2021; Accessed 2021 February 10]. Available from URL: https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897.html#
  34. 34.↵
    1. Griffin MP,
    2. Yuan Y,
    3. Takas T,
    4. Domachowske JB,
    5. Madhi SA,
    6. Manzoni P, et al.
    Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383: 415–425.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords